NCT07400523 2026-04-17
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
Clinical Trials
8 trialsNCT06377852 2026-03-18
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
NCT07237256 2026-03-16
NoLEEta
UNICANCER
Phase 3 Recruiting
NCT06585969 2026-02-12
DISCORDANT
Danish Breast Cancer Cooperative Group
Phase 3 Withdrawn
NCT04055493 2025-08-26
ADAPTcycle
West German Study Group
Phase 3 Active not recruiting
NCT05207709 2025-04-29
HARMONIA
SOLTI Breast Cancer Research Group
Phase 3 Active not recruiting
NCT02344472 2024-06-04
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Phase 3 Active not recruiting
NCT03905343 2021-06-16
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
Swiss Cancer Institute
Phase 3 Terminated